Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

MICROBIOLOGY AND IMMUNOLOGY, an esteemed journal published by WILEY, serves as a vital resource for researchers and professionals in the fields of microbiology, immunology, and virology. With its ISSN 0385-5600 and E-ISSN 1348-0421, this journal has been a cornerstone in scientific literature since its inception in 1977, bridging decades of research and innovation through its comprehensive coverage of emerging trends and discoveries. Although this journal operates without open access, it maintains a commendable presence in academic circles, reflected in its 2023 Quartile rankings of Q3 across the categories of Immunology, Microbiology, and Virology. As part of an important discourse in these disciplines, MICROBIOLOGY AND IMMUNOLOGY ensures its scholarly contributions are relevant to both seasoned researchers and emerging scholars. Positioned in a competitive journal landscape, with Scopus ranks indicating a median percentile across its fields, it remains committed to advancing knowledge through peer-reviewed articles, thereby supporting the continuous evolution of its focus areas. The journal's current scope encompasses topics critical for understanding pathogen-host interactions and the immune response, making it a crucial publication for any academic library or individual scholar dedicated to the biological sciences.

Future Science OA is an esteemed open-access journal published by FUTURE SCI LTD, dedicated to advancing knowledge in the fields of biotechnology and medicine. Established in 2015, this journal has rapidly gained recognition within the scientific community, evidenced by its impressive ranking in both General Medicine (Rank #100/636, 84th percentile) and Biotechnology (Rank #145/311, 53rd percentile) as per Scopus metrics. With a Q2 category quartile in both fields as of 2023, Future Science OA provides a vital platform for researchers, professionals, and students to share groundbreaking research and innovative ideas. Notably, being an open-access journal allows for a wider dissemination of knowledge, ensuring equal access to high-quality research for practitioners and scholars alike. Based in the United Kingdom, Future Science OA is committed to fostering collaboration and dialogue within the scientific community, making it a cornerstone resource for advancing the future of the life sciences.

REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO is a prestigious open-access journal that has been publishing significant research in the field of tropical medicine since its inception in 1961. Produced by the Instituto de Medicina Tropical de São Paulo, the journal boasts a commendable Q3 ranking in both the categories of Infectious Diseases and Medicine (miscellaneous), as per the latest 2023 metrics. With an ISSN of 0036-4665 and E-ISSN of 1678-9946, it serves as a prominent platform for scholars and professionals to disseminate their findings and insights on pressing health issues prevalent in tropical regions, particularly those relevant to Brazil and beyond. This journal is essential for researchers and practitioners who seek to advance their understanding and apply innovative solutions in tropical medicine, thus addressing the distinct challenges posed by infectious diseases in diverse populations. The journal is accessible through various open access platforms, ensuring that critical research is available to a global audience, fostering knowledge sharing and collaboration.

BIOLOGICALS, published by Academic Press Ltd - Elsevier Science Ltd, is a prestigious journal dedicated to advancing the fields of applied microbiology, biotechnology, immunology, and pharmacology. With an ISSN of 1045-1056 and E-ISSN of 1095-8320, this journal has established itself as a vital resource for researchers and practitioners, offering rigorous peer-reviewed content that spans converging disciplines from 1990 to 2024. With a commendable presence in the field, it ranks in the Q3 category across multiple domains, including applied microbiology and biotechnology, highlighting its contribution to critical advancements and knowledge dissemination. The journal's rankings reflect its relevance, with notable placements in Scopus Ranks, ensuring it remains an important platform for innovative research and discussion. Although it does not currently offer Open Access, the journal’s comprehensive review process guarantees the quality of published work, making it essential reading for professionals, academics, and students seeking to stay informed about the latest developments in biology and life sciences.

The JOURNAL OF INFECTIOUS DISEASES, published by OXFORD UNIV PRESS INC, is a leading peer-reviewed journal dedicated to advancing the understanding of infectious diseases through high-quality research. With an impressive impact factor reflecting its prominence in the field—ranking in the Q1 category for both Immunology and Allergy and Infectious Diseases—this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike. Its extensive history, spanning over a century since its inception in 1904, highlights its established authority and commitment to the field. Based in the United Kingdom, the journal covers essential topics from clinical management to epidemiological trends, providing vital insights that inform practice and policy. Although the journal is not open access, it remains accessible to a wide audience, ensuring that critical research continues to drive innovation and best practices in infectious disease management.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

Human Vaccines & Immunotherapeutics, published by TAYLOR & FRANCIS INC, stands at the forefront of immunology and vaccine research, presenting critical advancements and innovative approaches to immunotherapy since its inception in 2012. With an impressive impact factor and rankings in the top quartiles of leading categories such as Immunology, Pharmacology, and Medicine, this journal serves as a vital resource for researchers, healthcare professionals, and students who are dedicated to advancing the understanding and application of vaccines and immunotherapeutic strategies. Offering Open Access options for enhanced visibility and outreach, the journal encourages the dissemination of high-quality research that can drive meaningful impact in public health. Its continuous commitment to excellence is reflected in its ranking metrics—ranking #71 in Pharmacology with a 77th percentile and #69 in Immunology and Allergy with a 70th percentile, ensuring that it remains a preferred forum for notable scholarly contributions in a rapidly evolving field.

SEXUALLY TRANSMITTED DISEASES is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the investigation and dissemination of research on sexually transmitted infections and related public health issues. This journal, with the ISSN 0148-5717 and E-ISSN 1537-4521, has been a cornerstone of the field since its inception in 1977, with coverage extended to 2024. A testament to its scholarly impact, it holds prestigious rankings in the top quartiles across various categories including Q1 in Dermatology and Q1 in Public Health, Environmental and Occupational Health, underscoring its importance in driving forward critical discussions and advancements in these vital areas of health. With an emphasis on rigorous research and the latest scientific findings, the journal not only serves researchers and professionals but also informs clinical practices, shaping public health policies. While it is not an Open Access journal, it offers a wealth of subscription-based resources highly regarded for their quality and relevance within the medical community.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.